Navigation Links
Viral Genetics Completes Second Major Debt Conversion
Date:8/26/2009

nd indicate "Viral Genetics" as the source.

ABOUT VIRAL GENETICS, INC.:

Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV, AIDS and other autoimmune diseases using its thymus nuclear protein compound (TNP). The company recently entered into an Exclusive License Agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the Company) to license technology developed by M. Karen Newell, PhD, that appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials. Viral Genetics believes that its investigational HIV/AIDS drug based on TNP, called VGV-1, represents a unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. As a type of immune-based therapy, it focuses on boosting the immune system to allow the body to fight HIV more efficiently. VGV-1 has been studied in five human clinical trials for the treatment of HIV/AIDS. Online at www.viralgenetics.com

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurat
'/>"/>

SOURCE Viral Genetics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. NIAID Awards New Grant to Expand Studies of Peregrines Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers
2. MinuteClinic Offers New Rapid Pink-Eye Test; Detects Viral Conjunctivitis Infections in Minutes
3. Surprise! Better Sleep with Gene-Eden(R), an Antiviral Supplement
4. HIV integrase inhibitor effective for patients beginning antiretroviral treatment
5. Earlier HIV antiviral treatment can be cost effective in areas of limited resources
6. Adenoviral vector specifically targeted to EphA2 receptor in pancreatic cancer cells
7. Vaporized viral vector shows promise in anti-cancer gene therapy
8. MicroRNA regulation of tumor-killing viruses avoids unwanted viral pathology
9. Viral Genetics Has Option Under Issued Key Patent for Cancer Drug
10. CORRECTION: Viral Genetics Pursues Promising New Therapy for Lyme Disease With Grant from Time for Lyme, Inc.
11. National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a ... insurance policy . , Some types of vehicles cannot be ... newly released blog post to see if their vehicle qualifies for ... are some of the cars that cannot be covered by a ...
(Date:12/26/2014)... TX (PRWEB) December 26, 2014 The US ... in this report. In 2013, GlobalData’s forecast estimates that sales ... largest CRC market due to the high incidence of the ... with the 5EU, Japan, and China. Increased sales of CRC ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... delivers immediate cost savings for http://www.lle-inc.com/link.html [24-hour telephone ... or seeking multilingual solutions. , ... ... LLE® http://www.lle-inc.com/index.html [(Language Learning Enterprises, Inc.)], a leading ...
... firm represents Pickerington man who contracted E. coli from ground beef ... ... (Lexis Nexis) July 25, 2008 -- http://www.donaheyohioinjurylawyers.com [The Donahey ... central Ohio, has filed a product liability lawsuit in Franklin County ...
... Colo., July 24 An Arapahoe County District,Court ... likely,amount to more than $1 million in damages ... of Inverness-based Verex, Inc., a public,company, and a ... found that PR Pharmaceuticals and its President, Steven ...
... Pa., July 24 HTH Worldwide, a global ... will begin offering its,CityHealth(R) Profiles to Living Abroad.com ... fact-filled online guides to trusted,medical care in hundreds ... tools and destination-driven information for those living,overseas or ...
... the commonest cause of blindness in the western ... the immune system influence the risk of contracting ... working in co-operation with researchers from Gttingen, Regensburg ... time, demonstrated that in cases of senile blindness ...
... sports,chiropractor, Dr. Camille Reagan to serve as a member ... Beijing. Dr. Reagan has extensive,experience in the international sports ... 2007 Pan American Games in Rio de Janeiro., ... an international sports,platform," said Dr. Reagan. "The athletes believe ...
Cached Medicine News:Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3Health News:Donahey Law Firm Files E. Coli Product Liability Lawsuit Against Kroger Company in Franklin County Court 2Health News:Jury Award to Englewood Company to Total More Than $1 Million for Breach of Fiduciary Duties in Shareholder Class Action Case 2Health News:HTH Worldwide to Provide International Health Guide to Living Abroad.com 2Health News:Hyperactive immune resistance brings blindness in old age 2Health News:Colombia Appoints Dallas Chiropractor to Olympic Team 2
(Date:1/23/2015)... , Jan. 23, 2015  Now available for sale, The ... support that prevents ankle sprains by cushioning the ankle ... fits securely around the outside of any shoe type ... comfort while still offering protection against sprains. With customers ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... 2015   Leatt Corporation  (OTCQB: LEAT), a global developer, ... forms of sports, including extreme motor sports, and whose ... that the UISP Lega Motociclismo Lombardia, an Italian motocross ... wear a neck brace during its racing competitions.  ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3
... an international generic pharmaceuticals company, today announced that it ... Administration to market Valacyclovir Hydrochloride Tablets.     ... generic equivalent of Valtrex® by GlaxoSmithKline, had US sales ... December 31, 2010, according to IMS Health.     ...
... 2011 Amgen (Nasdaq: AMGN ) today ... and fifth years of Prolia® (denosumab) treatment, postmenopausal women ... year-over-year increases in lumbar spine and total hip bone ... The overall adverse event profile was similar for the ...
Cached Medicine Technology:Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S. 2Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 2Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 3Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 4Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 5Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 6Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 7Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 8Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 9
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: